Emerging therapeutic options for sporadic inclusion body myositis

References

• PaltielADIngvarssonELeeDKDemographic and clinical features of inclusion body myositis in north AmericaMuscle Nerve Epub12302014
   Web of Science ®Google Scholar
• FlacheneckerPEpidemiology of neuroimmunological diseasesJ Neurol2006253Suppl 5V2V816998750
   PubMedGoogle Scholar
• CorteseAMachadoPMorrowJLongitudinal observational study of sporadic inclusion body myositis: implications for clinical trialsNeuromuscul Disord20132340441223489664
   PubMed Web of Science ®Google Scholar
• LynnSJSawyersSMMollerPWO’DonnellJLChapmanPTAdult-onset inflammatory myopathy: North Canterbury experience 1989–2001Intern Med J200535317017315737137
   PubMed Web of Science ®Google Scholar
• MeyerAMeyerNSchaefferMGottenbergJEGenyBSibiliaJIncidence and prevalence of inflammatory myopathies: a systematic reviewRheumatology (Oxford)2015541506325065005
   PubMed Web of Science ®Google Scholar
• WilsonFCYtterbergSRSt SauverJLReedAMEpidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, MinnesotaJ Rheumatol200835344544718203321
   PubMed Web of Science ®Google Scholar
• GreenbergSABiomarkers of inclusion body myositisCurr Opin Rheumatol201325675376224067380
   PubMed Web of Science ®Google Scholar
• HerbertMKStammen-VogelzangsJVerbeekMMDisease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseasesAnn Rheum Dis Epub2242015
   PubMed Web of Science ®Google Scholar
• JoshiPRVetterkeMHauburgerATacikPStoltenburgGHanischFFunctional relevance of mitochondrial abnormalities in sporadic inclusion body myositisJ Clin Neurosci2014211959196325311418
   PubMed Web of Science ®Google Scholar
• LloydTEChristopher-StineLPinal-FernandezICytosolic 5′-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseasesArthritis Care Res Epub4172015
   Web of Science ®Google Scholar
• MorosettiRGliubizziCSancriccaCTWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesisAm J Pathol20121801603161322314077
   PubMed Web of Science ®Google Scholar
• MoussaCEFuQKumarPTransgenic expression of β-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathologyFASEB J200620122165216716940437
   PubMed Web of Science ®Google Scholar
• PinkusJLAmatoAATaylorJPGreenbergSAAbnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositisNeuromuscul Disord20142461161624857366
   PubMed Web of Science ®Google Scholar
• RygielKAMillerJGradyJPRochaMCTaylorRWTurnbullDMMitochondrial and inflammatory changes in sporadic inclusion body myositisNeuropathol Appl Neurobiol201541328830324750247
   PubMed Web of Science ®Google Scholar
• GriggsRCAskanasVDiMauroSInclusion body myositis and myopathiesAnn Neurol1995387057137486861
   PubMed Web of Science ®Google Scholar
• Hilton-JonesDMillerAPartonMHoltonJSewryCHannaMGInclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008Neuromuscul Disord20102014214720074951
   PubMedGoogle Scholar
• RoseMRGroupEIW188th ENMC International workshop: inclusion body myositis, 2–4 December 2011, Naarden, The NetherlandsNeuromuscul Disord2013231044105524268584
   PubMed Web of Science ®Google Scholar
• LazarouINGuernePAClassification, diagnosis, and management of idiopathic inflammatory myopathiesJ Rheumatol20134055056423504386
   PubMed Web of Science ®Google Scholar
• MachadoPMDimachkieMMBarohnRJSporadic inclusion body myositis: new insights and potential therapyCurr Opin Neurol20142759159825159931
   PubMed Web of Science ®Google Scholar
• MastagliaFLNeedhamMInclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approachesJ Clin Neurosci20152261325510538
   PubMed Web of Science ®Google Scholar
• NeedhamMCorbettADayTChristiansenFFabianVMastagliaFLPrevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosisJ Clin Neurosci2008151350135318815046
   PubMed Web of Science ®Google Scholar
• CoxFMTitulaerMJSontJKWintzenARVerschuurenJJBadrisingUAA 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilitiesBrain20111343167317521908393
   PubMed Web of Science ®Google Scholar
• ErikssonMLindbergCHand function in 45 patients with sporadic inclusion body myositisOccup Ther Int20121910811622495756
   PubMed Web of Science ®Google Scholar
• BenvenisteOGuiguetMFreebodyJLong-term observational study of sporadic inclusion body myositisBrain20111343176318421994327
   PubMed Web of Science ®Google Scholar
• LindbergCOldforsAPrognosis and prognostic factors in sporadic inclusion body myositisActa Neurol Scand201212535335821916852
   PubMed Web of Science ®Google Scholar
• AllenbachYBenvenisteODecostreVQuadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositisNeuromuscul Disord20122298098622738680
   PubMed Web of Science ®Google Scholar
• HogrelJYAllenbachYCanalAFour-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trialsNeuromuscul Disord20142460461024857365
   PubMed Web of Science ®Google Scholar
• LowesLPAlfanoLViolletLKnee extensor strength exhibits potential to predict function in sporadic inclusion-body myositisMuscle Nerve20124516316822246869
   PubMed Web of Science ®Google Scholar
• RoseMRMcDermottMPThorntonCAPalenskiCMartensWBGriggsRCA prospective natural history study of inclusion body myositis: implications for clinical trialsNeurology20015754855011502935
   PubMed Web of Science ®Google Scholar
• JacksonCEBarohnRJGronsethGPandyaSHerbelinLMuscle Study GroupInclusion body myositis functional rating scale: a reliable and valid measure of disease severityMuscle Nerve20083747347618236463
   PubMed Web of Science ®Google Scholar
• LotzBPEngelAGNishinoHStevensJCLitchyWJInclusion body myositis. Observations in 40 patientsBrain1989112Pt 37277472543478
   PubMed Web of Science ®Google Scholar
• OhTHBrumfieldKAHoskinTLKasperbauerJLBasfordJRDysphagia in inclusion body myositis: clinical features, management, and clinical outcomeAm J Phys Med Rehabil20088788388918936555
   PubMed Web of Science ®Google Scholar
• KoEHRubinADDysphagia due to inclusion body myositis: case presentation and review of the literatureAnn Otol Rhinol Laryngol201412360560824634148
   PubMed Web of Science ®Google Scholar
• BalloPChiodiLCameliMDilated cardiomyopathy and inclusion body myositisNeurol Sci20123336737021922313
   PubMed Web of Science ®Google Scholar
• FinstererJStollbergerCKovacsGGSehnalELeft ventricular hypertrabeculation/noncompaction coincidentally found in sporadic inclusion body myositisInt J Cardiol201316861061223462629
   PubMed Web of Science ®Google Scholar
• InamoriYHiguchiIInoueTInclusion body myositis coexisting with hypertrophic cardiomyopathy: an autopsy studyNeuromuscul Disord20122274775422560514
   PubMed Web of Science ®Google Scholar
• UtzWSchmidtSSchulz-MengerJLuftFSpulerSCardiac involvement in sporadic inclusion-body myositisCirculation201012170670820142463
   PubMed Web of Science ®Google Scholar
• Della MarcaGSancriccaCLosurdoASleep disordered breathing in a cohort of patients with sporadic inclusion body myositisClin Neurophysiol20131241615162123583020
   PubMed Web of Science ®Google Scholar
• Rodriguez CruzPMNeedhamMHollingsworthPMastagliaFLHillmanDRSleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositisNeuromuscul Disord2014241036104125227894
   PubMed Web of Science ®Google Scholar
• BradySSquierWHilton-JonesDClinical assessment determines the diagnosis of inclusion body myositis independently of pathological featuresJ Neurol Neurosurg Psychiatry2013841240124623864699
   PubMed Web of Science ®Google Scholar
• SayersMEChouSMCalabreseLHInclusion body myositis: analysis of 32 casesJ Rheumatol199219138513891331441
   PubMed Web of Science ®Google Scholar
• LloydTEMammenALAmatoAAWeissMDNeedhamMGreenbergSAEvaluation and construction of diagnostic criteria for inclusion body myositisNeurology20148342643324975859
   PubMed Web of Science ®Google Scholar
• ChahinNEngelAGCorrelation of muscle biopsy, clinical course, and outcome in PM and sporadic IBMNeurology20087041842417881720
   PubMed Web of Science ®Google Scholar
• GirolamoFLiaAAmatiAOverexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositisNeuropathol Appl Neurobiol20133973674923452291
   PubMed Web of Science ®Google Scholar
• GreenbergSATheories of the pathogenesis of inclusion body myositisCurr Rheumatol Rep20101222122820425523
   PubMedGoogle Scholar
• HinikerADanielsBHLeeHSMargetaMComparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathiesActa Neuropathol Commun201312924252466
   PubMed Web of Science ®Google Scholar
• WeihlCCPestronkASporadic inclusion body myositis: possible pathogenesis inferred from biomarkersCurr Opin Neurol20102348248820664349
   PubMed Web of Science ®Google Scholar
• BenvenisteOStenzelWHilton-JonesDSandriMBoyerOvan EngelenBGAmyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chickenActa Neuropathol201512961162425579751
   PubMed Web of Science ®Google Scholar
• De BleeckerJLDe PaepeBAronicaE205th ENMC International workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28–30 March 2014, Naarden, The NetherlandsNeuromuscul Disord20152526827225572016
   PubMed Web of Science ®Google Scholar
• GreenbergSACytoplasmic 5′-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utilityMuscle Nerve20145048849224752512
   PubMed Web of Science ®Google Scholar
• LarmanHBSalajeghehMNazarenoRCytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositisAnn Neurol20137340841823596012
   PubMed Web of Science ®Google Scholar
• LuXPengQWangGDiscovery of new biomarkers of idiopathic inflammatory myopathyClin Chim Acta201544411712525681646
   PubMed Web of Science ®Google Scholar
• PlukHvan HoeveBJvan DoorenSHAutoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositisAnn Neurol20137339740723460448
   PubMed Web of Science ®Google Scholar
• MastagliaFLSporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHCActa Myol200928667120128139
   PubMedGoogle Scholar
• MastagliaFLNeedhamMScottASporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotypeNeuromuscul Disord20091976376519720533
   PubMed Web of Science ®Google Scholar
• Rojana-udomsartAJamesICastleyAHigh-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypesJ Neuroimmunol2012250778222633068
   PubMed Web of Science ®Google Scholar
• ScottAPLaingNGMastagliaFRecombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complexJ Neuroimmunol2011235778321543121
   PubMed Web of Science ®Google Scholar
• Rojana-udomsartAMitrpantCJamesIAnalysis of HLA-DRB3 alleles and supertypical genotypes in the MHC Class II region in sporadic inclusion body myositisJ Neuroimmunol201325417417723010279
   PubMed Web of Science ®Google Scholar
• GangQBettencourtCMachadoPMThe effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositisNeurobiol Aging2015361766.e1e325670332
   PubMed Web of Science ®Google Scholar
• TascaGMonforteMDe FinoCKleyRARicciEMirabellaMMRI pattern recognition in sporadic inclusion body myositisMuscle Nerve Epub2532015
   Web of Science ®Google Scholar
• DionECherinPPayanCMagnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositisJ Rheumatol2002291897190612233884
   PubMed Web of Science ®Google Scholar
• PhillipsBACalaLAThickbroomGWMelsomAZilkoPJMastagliaFLPatterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging studyMuscle Nerve2001241526153411745956
   PubMed Web of Science ®Google Scholar
• CoxFMReijnierseMvan RijswijkCSWintzenARVerschuurenJJBadrisingUAMagnetic resonance imaging of skeletal muscles in sporadic inclusion body myositisRheumatology (Oxford)2011501153116121288962
   PubMed Web of Science ®Google Scholar
• HinikerADanielsBHLeeHSMargetaMComparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathiesActa Neuropathol Commun201312924252466
   PubMed Web of Science ®Google Scholar
• ArnardottirSAlexandersonHLundbergIEBorgKSporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reactionJ Rehabil Med2003351313512610846
   PubMed Web of Science ®Google Scholar
• BarohnRJAmatoAASahenkZKisselJTMendellJRInclusion body myositis: explanation for poor response to immunosuppressive therapyNeurology199545130213047617187
   PubMed Web of Science ®Google Scholar
• HengstmanGJTer LaakHJvan EngelenBGvan VenrooijBGAnti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisoneJ Neurol Neurosurg Psychiatry20017070611336039
   PubMed Web of Science ®Google Scholar
• LindbergCPerssonLIBjorkanderJOldforsAInclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 casesActa Neurol Scand1994891231318191875
   PubMed Web of Science ®Google Scholar
• QuartuccioLDe MarchiGScottCAFerraccioliGBeltramiCADe VitaSTreatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune featuresClin Exp Rheumatol20072524625117543149
   PubMed Web of Science ®Google Scholar
• CherinPPelletierSTeixeiraAIntravenous immunoglobulin for dysphagia of inclusion body myositisNeurology20025832611805271
   PubMed Web of Science ®Google Scholar
• DalakasMCSoniesBDambrosiaJSekulECuplerESivakumarKTreatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled studyNeurology1997487127169065553
   PubMed Web of Science ®Google Scholar
• DoblougCWalle-HansenRGranJTMolbergOLong-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patientsClin Exp Rheumatol20123083884222935197
   PubMed Web of Science ®Google Scholar
• RecherMSahrbacherUBremerJArndtBSteinerUFontanaATreatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Rheumatol Int20123246947220044785
   PubMed Web of Science ®Google Scholar
• PatwaHSChaudhryVKatzbergHRae-GrantADSoYTEvidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology2012781009101522454268
   PubMed Web of Science ®Google Scholar
• BadrisingUAMaat-SchiemanMLFerrariMDComparison of weakness progression in inclusion body myositis during treatment with methotrexate or placeboAnn Neurol20025136937211891832
   PubMed Web of Science ®Google Scholar
• VordenbaumenSNeuen-JacobERichterJSchneiderMInclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximabClin Rheumatol20102955555820108015
   PubMed Web of Science ®Google Scholar
• BarohnRJHerbelinLKisselJTPilot trial of etanercept in the treatment of inclusion-body myositisNeurology200666S123S12416432140
   PubMed Web of Science ®Google Scholar
• DastmalchiMGrundtmanCAlexandersonHA high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathiesAnn Rheum Dis2008671670167718272672
   PubMed Web of Science ®Google Scholar
• DalakasMCRakocevicGSchmidtJEffect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositisBrain20091321536154419454532
   PubMed Web of Science ®Google Scholar
• GreenbergSAComment on alemtuzumab and inclusion body myositisBrain2010133e135 author reply e619892769
   PubMed Web of Science ®Google Scholar
• TerraccianoCNogalskaAEngelWKAskanasVIn AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3β activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositisJ Neurochem201011238939619878439
   PubMed Web of Science ®Google Scholar
• KitazawaMTrinhDNLaFerlaFMInflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3βAnn Neurol200864152418318434
   PubMed Web of Science ®Google Scholar
• DimachkieMMBarohnRJInclusion body myositisNeurol Clin201432629646vii25037082
   PubMed Web of Science ®Google Scholar
• KosmidisMLAlexopoulosHTzioufasAGDalakasMCThe effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot studyJ Neurol Sci201333412312523998706
   PubMed Web of Science ®Google Scholar
• ZongMDorphCDastmalchiMAnakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-upAnn Rheum Dis20147391392023625983
   PubMed Web of Science ®Google Scholar
• MorosettiRGliubizziCBroccoliniASancriccaCMirabellaMMesoangioblasts of inclusion-body myositis: a twofold tool to study pathogenic mechanisms and enhance defective muscle regenerationActa Myol201130242821842589
   PubMedGoogle Scholar
• MorosettiRMirabellaMGliubizziCMyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscleProc Natl Acad Sci U S A2006103169951700017077152
   PubMed Web of Science ®Google Scholar
• Northwestern UniversityStem cell transplantation in idiopathic inflammatory myopathy diseases Available from: https://clinicaltrials.gov/ct2/show/NCT00278564. ClinicalTrials.gov identifier: NCT00278564Accessed August 31, 2015
   Google Scholar
• Richard BarohnMDArimoclomol in sporadic inclusion body myositis Available from: https://clinicaltrials.gov/ct2/show/NCT00769860. ClinicalTrials.gov identifier: NCT00769860Accessed August 31, 2015
   Google Scholar
• LahoutiAHAmatoAAChristopher-StineLInclusion body myositis: updateCurr Opin Rheumatol20142669069625215417
   PubMed Web of Science ®Google Scholar
• MendellJRRodino-KlapacLSahenkZGene therapy for muscular dystrophy: lessons learned and path forwardNeurosci Lett2012527909922609847
   PubMed Web of Science ®Google Scholar
• MendellJRSahenkZMalikVA phase 1/2a follistatin gene therapy trial for becker muscular dystrophyMol Ther20152319220125322757
   PubMed Web of Science ®Google Scholar
• Lach-TrifilieffEMinettiGCSheppardKAn antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophyMol Cell Biol20143460661824298022
   PubMed Web of Science ®Google Scholar
• AmatoAASivakumarKGoyalNTreatment of sporadic inclusion body myositis with bimagrumabNeurology2014832239224625381300
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsEfficacy and safety of bimagrumab/BYM338 at 52 weeks on physical function, muscle strength, mobility in sIBM patients (RESILIENT) Available from: https://clinicaltrials.gov/ct2/show/NCT01925209. ClinicalTrials.gov identifier: NCT01925209Accessed August 31, 2015
   Google Scholar
• AlfanoLNLowesLPDvorchikIThe 2 min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositisNeuromuscul Disord20142422222624342281
   PubMed Web of Science ®Google Scholar